Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Researchers discover cells responsible for resistance to T-ALL treatment

T-cell acute lymphoblastic leukemia (T-ALL) is a cancer of the blood that affects mainly children, but also less frequently adults. In adults, although the response to treatment might be initially positive, relapses are common and have a poor prognosis.

17 Dec 2020

New class of targeted cancer drugs may prove effective in treating common types of leukemia

A new study by researchers in Cleveland Clinic's Taussig Cancer Institute and Lerner Research Institute describes a novel class of targeted cancer drugs that may prove effective in treating certain common types of leukemia.

15 Dec 2020

Pulmonary hypertension drug may become a treatment option for cancer

A drug used to treat pulmonary hypertension significantly reduced the capacity of tumor cells to migrate and invade other tissues in trials involving pancreatic, ovarian, breast cancer, and leukemia cell lines.

15 Dec 2020

New analysis method could pave the way for important breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.

11 Dec 2020

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR).

10 Dec 2020

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Early study data shows a 29% overall response rate, the favorable safety profile in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

8 Dec 2020

Study examines effect of low-dose vancomycin to treat clostridium difficile infection

Clostridium difficile infection (CDI) is inflammation of the colon caused by a bacteria called clostridium difficile and is the most common cause of infectious diarrhea in hospitalized patients.

8 Dec 2020

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.

7 Dec 2020

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

7 Dec 2020

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

7 Dec 2020

Clonal hematopoiesis can confer a health benefit in allogeneic transplants

Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don't have cancer.

7 Dec 2020

Study identifies multiple important genomic differences in BCL malignancies using genomic ancestry

B-cell lymphoma and leukemias (BCL) are a diverse set of malignancies. While the genomic landscape of many BCL subtypes has been described, genomic ancestry has rarely been explored.

6 Dec 2020

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial.

6 Dec 2020

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology Annual Meeting.

5 Dec 2020

Genetically engineered T cells can target, attack pathogenic T cells that cause Type 1 diabetes

A new study has found that a novel T cell genetically engineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy treatments.

3 Dec 2020

Cancer cells exhibit metabolic changes that make them vulnerable to ferroptosis

If there is a silver lining in cancer's chaotic biology, it's that the same traits that give cancer cells a growth advantage often present opportunities for sabotaging them.

2 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Combining cell engineering with machine learning to design living medicines for cancer

Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.

26 Nov 2020

Leukemia News and Research

Further Reading

Researchers discover cells responsible for resistance to T-ALL treatment

New class of targeted cancer drugs may prove effective in treating common types of leukemia

Pulmonary hypertension drug may become a treatment option for cancer

New analysis method could pave the way for important breakthroughs in immunotherapy

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Study examines effect of low-dose vancomycin to treat clostridium difficile infection

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Clonal hematopoiesis can confer a health benefit in allogeneic transplants

Study identifies multiple important genomic differences in BCL malignancies using genomic ancestry

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

Genetically engineered T cells can target, attack pathogenic T cells that cause Type 1 diabetes

Cancer cells exhibit metabolic changes that make them vulnerable to ferroptosis

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Combining cell engineering with machine learning to design living medicines for cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News